Compare Adaptive Biotechnologies Corp (ADPT) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs TKO Group Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while TKO Group Holdings Inc trades at $192.12 (market cap $14.51B). The key difference: TKO Group Holdings Inc is far larger — about 4.4× Adaptive Biotechnologies Corp's market cap, and TKO Group Holdings Inc pays a 1.61% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TKO | |
|---|---|---|
Market Cap | $3.33B | $14.51B |
Sector | Health | Technology |
52-Week High | $22.37 | $224.96 |
52-Week Low | $10.24 | $155.61 |
Enterprise Value | $3.19B | $18.69B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
TKO trades at $192.30, down 1.09% today, with a bearish technical signal. The stock shows mixed earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026. Revenue grew to $4.74B in 2025, with net income of $195.40M, though high P/E of 71.49 suggests premium valuation. Recent news includes a successful WWE-UFC doubleheader and an $800M share repurchase, indicating strong operational momentum.
Outlook remains positive with 84% analyst buy ratings and a $234 consensus target, but risks include earnings volatility and competitive pressures. The stock offers growth potential through live event demand and media deals, yet investors should monitor margin sustainability amid high valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
